Pharma Business - June 11, 2026
Camurus receives FDA setback for CAM2029 in US acromegaly review
Camurus has received a Complete Response Letter from the US Food and Drug Administration regarding its New Drug Application for CAM2029 (Oclaiz), a once-monthly octreotide treatment for patients with acromegaly.
In a new job - June 9, 2026
Orexo strengthens its business development efforts
The company is strengthening its focus on new partnerships through the appointment of Raheleh Nassaji as Senior Vice President Business Development.
Agreement - June 9, 2026
AlzeCure Pharma enters collaboration and out-licensing agreement with Lilly
AlzeCure Pharma has entered into a collaboration and out-licensing agreement with the pharmaceutical company Eli Lilly and Company regarding the global rights to the Alzheimer’s project Alzstatin ACD680.
Collaboration - June 8, 2026
Moberg Pharma and Karo Healthcare expand collaboration for MOB-015/Terclara to China
Moberg Pharma has entered into a license agreement with Karo Healthcare regarding the commercialization of the nail fungus drug MOB-015 (Terclara) in China through the rapidly growing cross-border e-commerce channel.
Clinical Trials - June 8, 2026
Pharmability submits clinical trial application for first-in-human Phase Ib study
Pharmability has announced the submission of a Clinical Trial Application (CTA) for TIR-C, the company's lead drug candidate for atopic dermatitis (eczema).
Pharma Business - June 5, 2026
Diamyd Medical provides business update
As part of an ongoing strategic review, the company has received several proposals from external parties, including formal non-binding Letters of Intent, as well as invitations to invest into various business opportunities, it states.
